

# TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2015 Nr. 87

## A. TITEL

*Overeenkomst ter bestrijding van doping;  
(met Bijlage)  
Straatsburg, 16 november 1989*

## B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in *Trb.* 1991, 8.

Voor correcties, zie *Trb.* 2014, 162.

In *Trb.* 1991, 8 dienen in de Engelse tekst opnieuw de volgende correcties te worden aangebracht.

Op blz. 2, in de preambule, negende alinea, laatste regel, dient de zinsnede „in Reykjavik” te worden vervangen door „at Reykjavik”.

Op blz. 6, in artikel 4, eerste lid, laatste regel, dient het woord „steriods” te worden vervangen door „steroids”.

Op blz. 10, in artikel 6, tweede lid, eerste regel, dient de zinsnede „undertake the encourage” te worden vervangen door „undertake to encourage”.

Op blz. 20, in artikel 16, eerste lid, vijfde regel, dient het woord „Statue” te worden vervangen door „Statute”.

Voor wijzigingen van de tekst van de Bijlage, zie rubriek J van *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40, *Trb.* 2004, 194 en rubriek B van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274, *Trb.* 2012, 243, *Trb.* 2014, 21 en *Trb.* 2014, 162.

Voor enkele correcties, zie *Trb.* 2008, 83 en *Trb.* 2009, 24.

De Commissie van Toezicht heeft tijdens haar 41<sup>ste</sup> Vergadering op 5 november 2014, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst<sup>1)</sup> van de wijziging luidt als volgt:

### **The 2015 prohibited list**

### **World Anti-Doping Code**

### **Date of entry into force: 1 January 2015**

In accordance with Article 4.2.2 of the World Anti-Doping Code, all *Prohibited Substances* shall be considered as “*Specified Substances*” except Substances in classes S1, S2, S.4.4, S.4.5, S6.a, and *Prohibited Methods* M1, M2 and M3.

*Substances and methods prohibited at all times  
(in- and out-of-competition)*

### *Prohibited substances*

#### *S0. Non-approved substances*

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

<sup>1)</sup> De Franse tekst is niet opgenomen.

## S1. Anabolic agents

Anabolic agents are prohibited.

### 1. Anabolic Androgenic Steroids (AAS)

#### a. Exogenous<sup>1)</sup> AAS, including:

**1-androstenediol** (5 $\alpha$ -androst-1-ene-3 $\beta$ ,17 $\beta$ -diol); **1-androstenedione** (5 $\alpha$ -androst-1-ene-3,17-dione); **bolandiol** (estr-4-ene-3 $\beta$ ,17 $\beta$ -diol); **bolasterone**; **boldenone**; **boldione** (androsta-1,4-diene-3,17-dione); **calusterone**; **clostebol**; **danazol** ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 $\alpha$ -ol); **dehydrochlormethyltestosterone** (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one); **desoxymethyltestosterone** (17 $\alpha$ -methyl-5 $\alpha$ -androst-2-en-17 $\beta$ -ol); **drostanolone**; **ethylestrenol** (19-norpregna-4-en-17 $\alpha$ -ol); **fluoxymesterone**; **formebolone**; **furazabol** (17 $\alpha$ -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 $\alpha$ -androstan-17 $\beta$ -ol); **gestrinone**; **4-hydroxytestosterone** (4,17 $\beta$ -dihydroxyandrost-4-en-3-one); **mestanolone**; **mestrolone**; **metandienone** (17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one); **metenolone**; **methandriol**; **methasterone** (17 $\beta$ -hydroxy-2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-3-one); **methyldienolone** (17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9-dien-3-one); **methyl-1-testosterone** (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one); **methylnortestosterone** (17 $\beta$ -hydroxy-17 $\alpha$ -methylestr-4-en-3-one); **methyltestosterone**; **metribolone** (methyltrienolone, 17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9,11-trien-3-one); **mibolerone**; **nandrolone**; **19-norandrostenedione** (estr-4-ene-3,17-dione); **norboletone**; **norclostebol**; **norethandrolone**; **oxabalone**; **oxandrolone**; **oxymesterone**; **oxymetholone**; **prostanazol** (17 $\beta$ -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 $\alpha$ -androstan-3-one); **quinbolone**; **stanozolol**; **stenbolone**; **1-testosterone** (17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one); **tetrahydrogestrinone** (17-hydroxy-18 $\alpha$ -homo-19-nor-17 $\alpha$ -pregna-4,9,11-trien-3-one); **trenbolone** (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).

#### b. Endogenous<sup>2)</sup> AAS when administered exogenously:

**Androstenediol** (androst-5-ene-3 $\beta$ ,17 $\beta$ -diol); **androstenedione** (androst-4-ene-3,17-dione); **dihydrotestosterone** (17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one); **prasterone** (dehydroepiandrosterone, DHEA, 3 $\beta$ -hydroxyandrost-5-en-17-one); **testosterone**; and their **metabolites** and **isomers**, including but not limited to: **5 $\alpha$ -androstane-3 $\alpha$ ,17 $\alpha$ -diol**; **5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol**; **5 $\alpha$ -androstane-3 $\beta$ ,17 $\alpha$ -diol**; **5 $\alpha$ -androstane-3 $\beta$ ,17 $\beta$ -diol**; **5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol**; **androst-4-ene-3 $\alpha$ ,17 $\alpha$ -diol**; **androst-4-ene-3 $\alpha$ ,17 $\beta$ -diol**; **androst-4-ene-3 $\beta$ ,17 $\alpha$ -diol**; **androst-5-ene-3 $\alpha$ ,17 $\alpha$ -diol**; **androst-5-ene-3 $\alpha$ ,17 $\beta$ -diol**; **androst-5-ene-3 $\beta$ ,17 $\alpha$ -diol**; **4-androstenediol** (androst-4-ene-3 $\beta$ ,17 $\beta$ -diol); **5-androstenedione** (androst-5-ene-3,17-dione); **androsterone** (3 $\beta$ -hydroxy-5 $\alpha$ -androstan-17-one); **epi-dihydrotestosterone**; **epitestosterone**; **etiocholanolone**; **7 $\alpha$ -hydroxy-DHEA**; **7 $\beta$ -hydroxy-DHEA**; **7-keto-DHEA**; **19-norandrosterone**; **19-noretiocholanolone**.

### 2. Other Anabolic Agents, including but not limited to:

**Clenbuterol**, **selective androgen receptor modulators** (SARMs, e.g. **andarine** and **ostarine**), **tibolone**, **zanol** and **zilpaterol**.

## S2. Peptide hormones, growth factors, related substances and mimetics

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

### 1. Erythropoietin-Receptor agonists:

1.1. **Erythropoiesis-Stimulating Agents** (ESAs) including e.g. **darbepoietin** (dEPO); **erythropoietins** (EPO); **EPO-Fc**; **EPO-mimetic peptides** (EMP), e.g. **CNTO 530** and **peginesatide**; and **methoxy polyethylene glycol-epoetin beta** (CERA);

1.2. **Non-erythropoietic EPO-Receptor agonists**, e.g. **ARA-290**, **asialo EPO** and **carbamyated EPO**;

2. **Hypoxia-inducible factor** (HIF) **stabilizers**, e.g. **cobalt** and **FG-4592**; and **HIF activators**, e.g. **argon**, **xenon**;

3. **Chorionic Gonadotrophin** (CG) and **Luteinizing Hormone** (LH) and their releasing factors, e.g. **buserelin**, **gonadorelin** and **triptorelin**, in males;

4. **Corticotrophins** and their releasing factors, e.g. **corticoorelin**;

5. **Growth Hormone** (GH) and its releasing factors including **Growth Hormone Releasing Hormone** (GHRH) and its analogues, e.g. **CJC-1295**, **sermorelin** and **tesamorelin**; **Growth Hormone Secretagogues** (GHS), e.g. **ghrelin** and **ghrelin mimetics**, e.g. **anamorelin** and **ipamorelin**; and **GH-Releasing Peptides** (GHRPs), e.g. **alexamorelin**, **GHRP-6**, **hexarelin** and **pralmorelin** (GHRP-2).

Additional prohibited growth factors:

**Fibroblast Growth Factors** (FGFs); **Hepatocyte Growth Factor** (HGF); **Insulin-like Growth Factor-1** (IGF-1) and its analogues; **Mechano Growth Factors** (MGFs); **Platelet-Derived Growth Factor** (PDGF); **Vascular-Endothelial Growth Factor** (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

<sup>1)</sup> "Exogenous" refers to a substance which is not ordinarily produced by the body naturally.

<sup>2)</sup> "Endogenous" refers to a substance which is ordinarily produced by the body naturally.

### S3. Beta-2-agonists

All **beta-2 agonists**, including all **optical isomers**, e.g. *d*- and *l*- where relevant, are prohibited.

Except:

- Inhaled **salbutamol** (maximum 1600 micrograms over 24 hours);
- Inhaled **formoterol** (maximum delivered dose 54 micrograms over 24 hours); and
- Inhaled **salmeterol** in accordance with the manufacturers' recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

### S4. Hormone and metabolic modulators

The following **hormone** and **metabolic modulators** are prohibited:

1. **Aromatase inhibitors** including, but not limited to: **aminoglutethimide; anastrozole; androsta-1,4,6-triene-3,17-dione** (androstatrienedione); **4-androstene-3,6,17 trione** (6-oxo); **exemestane; formestane; letrozole** and **testolactone**.
2. **Selective estrogen receptor modulators (SERMs)** including, but not limited to: **raloxifene; tamoxifen** and **toremifene**.
3. Other **anti-estrogenic substances** including, but not limited to: **clomiphene; cyclofenil** and **fulvestrant**.
4. **Agents modifying myostatin function(s)** including, but not limited, to: **myostatin inhibitors**.
5. **Metabolic modulators:**
  - 5.1. **Activators of the AMP-activated protein kinase (AMPK)**, e.g. **AICAR**; and **Peroxisome Proliferator Activated Receptor  $\delta$  (PPAR $\delta$ ) agonists**, e.g. **GW 1516**;
  - 5.2. **Insulins**;
  - 5.3. **Trimetazidine**.

### S5. Diuretics and masking agents

The following **diuretics** and **masking agents** are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

- **Desmopressin; probenecid; plasma expanders**, e.g. **glycerol** and intravenous administration of **albumin, dextran, hydroxyethyl starch** and **mannitol**.
- **Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides**, e.g. **benzoflumezide, chlorothiazide** and **hydrochlorothiazide; triamterene** and **vaptans**, e.g. **tolvaptan**.

Except:

- Drospirenone; pamabrom; and topical dorzolamide and brinzolamide.
- Local administration of felypressin in dental anaesthesia.

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an *Adverse Analytical Finding* unless the *Athlete* has an approved *TUE* for that substance in addition to the one granted for the diuretic or masking agent.

### Prohibited methods

#### M1. Manipulation of blood and blood components

The following are prohibited:

1. The *Administration* or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen.  
Including, but not limited to:  
**Perfluorochemicals; efaproxiral (RSR13)** and **modified haemoglobin products**, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

## M2. Chemical and physical manipulation

The following are prohibited:

1. *Tampering, or Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control*.  
Including, but not limited to:  
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

## M3. Gene doping

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.

### *Substances and methods prohibited in-competition*

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited *In-Competition*:

#### *Prohibited substances*

##### S6. Stimulants

All **stimulants**, including all **optical isomers**, e.g. *d*- and *l*- where relevant, are prohibited. Stimulants include:

a: Non-Specified Stimulants:

**Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; meso-carb; metamfetamine(*d*-); p-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phentermine; prenylamine and prolintane.**

A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants.

Including, but not limited to:

**Benzfetamine; cathine<sup>3)</sup>; cathinone and its analogues, e.g. mephedrone, methedrone, and  $\alpha$ -pyrrolidinovalerophenone; dimethylamphetamine; ephedrine<sup>4)</sup>; epinephrine<sup>5)</sup> (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamphetamine (parahydroxyamphetamine); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxyamphetamine; methylephedrine<sup>6)</sup>; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); pemoline; pentetrazol; phenethylamine and its derivatives; phenmetrazine; phenpromethamine; propylhexedrine; pseudoephedrine<sup>7)</sup>; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine), tuaminoheptane;**

and other substances with a similar chemical structure or similar biological effect(s).

Except:

Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2015 Monitoring Program<sup>8)</sup>.

##### S7. Narcotics

Prohibited:

**Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine; oxycodone; oxymorphone; pentazocine and pethidine.**

<sup>3)</sup> Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

<sup>4)</sup> Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

<sup>5)</sup> Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

<sup>6)</sup> Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

<sup>7)</sup> Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

<sup>8)</sup> Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2015 Monitoring Program, and are not considered *Prohibited Substances*.

## S8. Cannabinoids

Prohibited:

- **Natural**, e.g. **cannabis**, **hashish** and **marijuana**, or **synthetic  $\Delta^9$ -tetrahydrocannabinol** (THC).
- **Cannabimimetics**, e.g. "**Spice**", **JWH-018**, **JWH-073**, **HU-210**.

## S9. Glucocorticoids

All **glucocorticoids** are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

### *Substances prohibited in particular sports*

#### *P1. Alcohol*

Alcohol (**ethanol**) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Motorcycling (FIM)
- Powerboating (UIM)

#### *P2. Beta-blockers*

**Beta-blockers** are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated.

- Archery (WA)<sup>9)</sup>
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC)<sup>10)</sup>
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea.

Including, but not limited to:

**Acebutolol; alprenolol; atenolol; betaxolol; bisoprolol; bunolol; carteolol; carvedilol; celiprolol; esmolol; labetalol; levobunolol; metipranolol; metoprolol; nadolol; oxprenolol; pindolol; propranolol; sotalol and timolol.**

---

## C. VERTALING

Zie *Trb.* 1991, 8.

Voor correcties, zie *Trb.* 2014, 162.

## D. PARLEMENT

Zie *Trb.* 1995, 114.

## E. PARTIJGEGEVENS

Zie *Trb.* 1991, 8, rubriek F en rubriek H van *Trb.* 1995, 114 en, laatstelijk, *Trb.* 2014, 21.

---

<sup>9)</sup> Also prohibited *Out-of-Competition*

<sup>10)</sup> Also prohibited *Out-of-Competition*

## G. INWERKINGTREDING

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, rubriek J van *Trb.* 1996, 284, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40 en *Trb.* 2004, 194, en rubriek G van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274, *Trb.* 2012, 243, *Trb.* 2014, 21 en *Trb.* 2014, 162.

De wijziging van 5 november 2014 van de Bijlage bij de Overeenkomst is op 1 januari 2015 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten.

### Koninkrijk der Nederlanden

Land	Voorlopige toepassing	In werking	Terugwerkende kracht	Buiten werking
Nederland (in Europa)		01-06-1995		
Nederland (Bonaire)		10-10-2010		
Nederland (Sint Eustatius)		10-10-2010		
Nederland (Saba)		10-10-2010		
Aruba				
Curaçao		10-10-2010		
Sint Maarten		10-10-2010		
De Overeenkomst, met Bijlage, gold sinds 01-01-2009 voor de Nederlandse Antillen.				

## J. VERWIJZINGEN

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 2004, 194, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 274, *Trb.* 2012, 243, *Trb.* 2014, 21 en *Trb.* 2014, 162.

### Verbanden

Titel : Internationaal Verdrag tegen doping in de sport;  
Parijs, 19 oktober 2005  
Laatste *Trb.* : *Trb.* 2015, 88

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 5 november 2014 van de Bijlage zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de elfde juni 2015.

De Minister van Buitenlandse Zaken,

A.G. KOENDERS